In the last trading session, 0.21 million shares of the Adverum Biotechnologies Inc (NASDAQ:ADVM) were traded, and its beta was 0.74. Most recently the company’s share price was $2.21, and it changed around -$0.02 or -0.90% from the last close, which brings the market valuation of the company to $46.17M. ADVM currently trades at a discount to its 52-week high of $10.14, offering almost -358.82% off that amount. The share price’s 52-week low was $1.78, which indicates that the current value has risen by an impressive 19.46% since then.
Adverum Biotechnologies Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended ADVM as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Adverum Biotechnologies Inc is expected to report earnings per share of -2.29 for the current quarter.
Adverum Biotechnologies Inc (NASDAQ:ADVM) trade information
Instantly ADVM has showed a red trend with a performance of -0.90% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.55 on recent trading dayincreased the stock’s daily price by 13.33%. The company’s shares are currently down -52.68% year-to-date, but still up 4.49% over the last five days. On the other hand, Adverum Biotechnologies Inc (NASDAQ:ADVM) is -25.59% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $15, which translates to bulls needing to increase their stock price by 85.27% from its current value. Analyst projections state that ADVM is forecast to be at a low of $2 and a high of $28.
Adverum Biotechnologies Inc (ADVM) estimates and forecasts
The year-over-year growth rate is expected to be -81.00%, down from the previous year.
Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.03%. Adverum Biotechnologies Inc earnings are expected to increase by 8.28% in 2025, but the outlook is positive 12.12% per year for the next five years.
ADVM Dividends
Adverum Biotechnologies Inc’s next quarterly earnings report is expected to be released in June.
BML CAPITAL MANAGEMENT, LLC, with 9.4284% or 1.97 million shares worth $13.49 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 624.74 shares worth $1.38 million, making up 2.99% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 586.25 shares worth around $1.3 million, which represents about 2.81% of the total shares outstanding.
